

Marina B Klein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3862639/publications.pdf>

Version: 2024-02-01

245
papers

11,350
citations

28274

55
h-index

36028

97
g-index

250
all docs

250
docs citations

250
times ranked

12420
citing authors

#	ARTICLE	IF	CITATIONS
1	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS ONE, 2013, 8, e81355.	2.5	1,111
2	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal of Medicine, 2009, 360, 1815-1826.	27.0	986
3	Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. Clinical Infectious Diseases, 2012, 54, 1026-1034.	5.8	453
4	Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Research and Human Retroviruses, 2016, 32, 50-58.	1.1	231
5	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society's Lancet Commission. Lancet, The, 2018, 392, 312-358.	13.7	230
6	Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus-Monoinfected Patients. Annals of Internal Medicine, 2014, 160, 369-379.	3.9	214
7	Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 149-163.	2.1	188
8	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. Clinical Infectious Diseases, 2010, 50, 1512-1520.	5.8	187
9	Invasive Cervical Cancer Risk Among HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 405-413.	2.1	184
10	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). International Journal of Epidemiology, 2007, 36, 294-301.	1.9	176
11	Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sexually Transmitted Infections, 2012, 88, 558-564.	1.9	146
12	End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases, 2015, 60, 941-949.	5.8	142
13	Retention Among North American HIV-Infected Persons in Clinical Care, 2000-2008. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 356-362.	2.1	131
14	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases, 2018, 66, 1230-1238.	5.8	131
15	Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?. Journal of the International AIDS Society, 2017, 20, 22146.	3.0	126
16	Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiology and Drug Safety, 2011, 20, 689-699.	1.9	123
17	Seroprevalence of Chronic Hepatitis B Virus Infection and Prior Immunity in Immigrants and Refugees: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e44611.	2.5	123
18	U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008. Annals of Internal Medicine, 2012, 157, 325.	3.9	106

#	ARTICLE	IF	CITATIONS
19	Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis. <i>Journal of Infectious Diseases</i> , 2012, 205, 1230-1238.	4.0	103
20	Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. <i>BMC Infectious Diseases</i> , 2015, 15, 274.	2.9	103
21	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. <i>Cmaj</i> , 2022, 194, E242-E251.	2.0	103
22	The Impact of Hepatitis C Virus Coinfection on HIV Progression Before and After Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 365-372.	2.1	94
23	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. <i>Lancet HIV</i> , 2019, 6, e93-e104.	4.7	94
24	The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. <i>Cmaj</i> , 2018, 190, E677-E687.	2.0	93
25	Virologic and immunologic response to HAART, by age and regimen class. <i>Aids</i> , 2010, 24, 2469-2479.	2.2	92
26	Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. <i>International Journal of Epidemiology</i> , 2010, 39, 1162-1169.	1.9	91
27	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	5.8	90
28	Leukocyte infection by the granulocytic ehrlichiosis agent is linked to expression of a selectin ligand. <i>Journal of Clinical Investigation</i> , 1999, 103, 407-412.	8.2	89
29	HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. <i>European Journal of Immunology</i> , 2010, 40, 2493-2505.	2.9	87
30	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μ L in Europe and North America: a pooled cohort observational study. <i>Lancet</i> , 2010, 376, 340-345.	13.7	82
31	Influenzavirus Infection Is a Primary Cause of Febrile Respiratory Illness in HIV-Infected Adults, Despite Vaccination. <i>Clinical Infectious Diseases</i> , 2007, 45, 234-240.	5.8	79
32	Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. <i>Aids</i> , 2016, 30, 2635-2643.	2.2	78
33	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. <i>Oral Oncology</i> , 2014, 50, 1169-1176.	1.5	77
34	Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus-Infected, and Uninfected Patients. <i>Clinical Infectious Diseases</i> , 2014, 58, 1449-1458.	5.8	77
35	The Agent of Human Granulocytic Ehrlichiosis Induces the Production of Myelosuppressing Chemokines without Induction of Proinflammatory Cytokines. <i>Journal of Infectious Diseases</i> , 2000, 182, 200-205.	4.0	75
36	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. <i>CMAJ Open</i> , 2016, 4, E605-E614.	2.4	74

#	ARTICLE	IF	CITATIONS
37	The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0141715.	2.5	74
38	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. AIDS Research and Therapy, 2010, 7, 45.	1.7	73
39	Association Between Food Insecurity and HIV Viral Suppression: A Systematic Review and Meta-Analysis. AIDS and Behavior, 2017, 21, 754-765.	2.7	73
40	Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV/HCV coinfection before and after antiretroviral therapy. Aids, 2010, 24, 1857-1865.	2.2	71
41	Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion. JAMA Internal Medicine, 2015, 175, 178.	5.1	71
42	Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. Journal of Hepatology, 2017, 67, 801-808.	3.7	70
43	Predictors of CD4:CD8 Ratio Normalization and Its Effect on Health Outcomes in the Era of Combination Antiretroviral Therapy. PLoS ONE, 2013, 8, e77665.	2.5	67
44	Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 413-421.	2.1	67
45	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clinical Infectious Diseases, 2017, 65, 636-643.	5.8	67
46	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	12.8	67
47	Differences in resistance mutations among HIV-1 non-B subtype B infections: a systematic review of evidence (1996-2008). Journal of the International AIDS Society, 2009, 12, 11-11.	3.0	65
48	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. Clinical Infectious Diseases, 2014, 58, 1185-1189.	5.8	65
49	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. Clinical Infectious Diseases, 2016, 62, 919-926.	5.8	65
50	Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clinical Infectious Diseases, 2017, 64, 1154-1162.	5.8	64
51	Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study. Clinical Infectious Diseases, 2014, 59, 1579-1587.	5.8	63
52	Marijuana Smoking Does Not Accelerate Progression of Liver Disease in HIV/Hepatitis C Coinfection: A Longitudinal Cohort Analysis. Clinical Infectious Diseases, 2013, 57, 663-670.	5.8	62
53	Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Reviews, 2008, 10, 212-23.	1.0	61
54	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases, 2016, 63, ciw531.	5.8	60

#	ARTICLE	IF	CITATIONS
55	Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865.	2.2	59
56	Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor–Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2021, 73, e2234-e2242.	5.8	59
57	Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 44, 463-469.	2.1	58
58	Impact of Round-the-Clock, Rapid Oral Fluid HIV Testing of Women in Labor in Rural India. <i>PLoS Medicine</i> , 2008, 5, e92.	8.4	58
59	Peering at peer review revealed high degree of chance associated with funding of grant applications. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 842-848.	5.0	57
60	Envisioning Women-Centered HIV Care: Perspectives from Women Living with HIV in Canada. <i>Women's Health Issues</i> , 2017, 27, 721-730.	2.0	56
61	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy–Experienced Patients with HIV Infection in North America. <i>Clinical Infectious Diseases</i> , 2009, 49, 1582-1590.	5.8	55
62	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475.	5.8	53
63	Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for Determination of HIV-1 Viral Loads in a Cohort of Canadian Patients with Diverse HIV Subtype Infections. <i>Journal of Clinical Microbiology</i> , 2011, 49, 118-124.	3.9	53
64	Disparities in direct acting antivirals uptake in HIV–hepatitis C co-infected populations in Canada. <i>Journal of the International AIDS Society</i> , 2017, 20, e25013.	3.0	52
65	Pathways From HIV-Related Stigma to Antiretroviral Therapy Measures in the HIV Care Cascade for Women Living With HIV in Canada. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 144-153.	2.1	52
66	Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. <i>Aids</i> , 2011, 25, 777-786.	2.2	51
67	Mortality in HIV–hepatitis C co-infected patients in Canada compared to the general Canadian population (2003–2013). <i>Aids</i> , 2014, 28, 1957-1965.	2.2	50
68	Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans. <i>Clinical Infectious Diseases</i> , 2014, 58, 719-727.	5.8	50
69	Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review. <i>International Journal of Drug Policy</i> , 2018, 57, 95-103.	3.3	50
70	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus–coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 821-829.	5.8	48
71	Hepatitis B Screening and Vaccination Strategies for Newly Arrived Adult Canadian Immigrants and Refugees: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2013, 8, e78548.	2.5	47
72	Is Antiretroviral Therapy Causing Long-Term Liver Damage? A Comparative Analysis of HIV-Mono-Infected and HIV/Hepatitis C Co-Infected Cohorts. <i>PLoS ONE</i> , 2009, 4, e4517.	2.5	46

#	ARTICLE	IF	CITATIONS
73	Food insecurity and low CD4 count among HIV-infected people: a systematic review and meta-analysis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1577-1585.	1.2	46
74	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV</i> , 2019, 6, e240-e249.	4.7	46
75	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2013, 208, 1240-1249.	4.0	43
76	Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 62-72.	2.1	43
77	Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. <i>International Journal of Drug Policy</i> , 2021, 96, 103247.	3.3	43
78	CD8+ T-Cell Response Promotes Evolution of Hepatitis C Virus Nonstructural Proteins. <i>Gastroenterology</i> , 2011, 140, 2064-2073.	1.3	42
79	Physicians' Practices for Diagnosing Liver Fibrosis in Chronic Liver Diseases: A Nationwide, Canadian Survey. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 23-30.	1.9	42
80	Cohort Profile: The Canadian Observational Cohort collaboration. <i>International Journal of Epidemiology</i> , 2011, 40, 25-32.	1.9	41
81	A CD4+ Cell Count <200 Cells per Cubic Millimeter at 2 Years After Initiation of Combination Antiretroviral Therapy Is Associated With Increased Mortality in HIV-Infected Individuals With Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 451-459.	2.1	40
82	Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. <i>Journal of the International AIDS Society</i> , 2018, 21, e25051.	3.0	40
83	Gender Differences in Clinical Outcomes among HIV-Positive Individuals on Antiretroviral Therapy in Canada: A Multisite Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83649.	2.5	39
84	HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. <i>HIV Medicine</i> , 2013, 14, 10-20.	2.2	38
85	Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. <i>Aids</i> , 2009, 23, 731-737.	2.2	38
86	Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults. <i>PLoS ONE</i> , 2011, 6, e17758.	2.5	38
87	Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. <i>BMC Infectious Diseases</i> , 2016, 16, 590.	2.9	36
88	Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. <i>Liver International</i> , 2019, 39, 2244-2260.	3.9	36
89	Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review. <i>Journal of the International AIDS Society</i> , 2014, 17, 18944.	3.0	35
90	Epidemiology of hepatitis C virus in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 297-302.	3.8	34

#	ARTICLE	IF	CITATIONS
91	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	4.0	33
92	HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. <i>Vaccine</i> , 2016, 34, 4799-4806.	3.8	33
93	Screening for nonalcoholic steatohepatitis by using cyokeratin 18 and transient elastography in HIV mono-infection. <i>PLoS ONE</i> , 2018, 13, e0191985.	2.5	33
94	The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2019, 68, 788-794.	5.8	32
95	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. <i>American Journal of Epidemiology</i> , 2019, 188, 2097-2109.	3.4	32
96	Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV–hepatitis C virus co-infection. <i>Aids</i> , 2011, 25, 967-975.	2.2	31
97	A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. <i>BMC Infectious Diseases</i> , 2017, 17, 140.	2.9	31
98	Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028 study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. <i>BMJ Open</i> , 2019, 9, e024793.	1.9	31
99	Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, 363-371.	5.8	31
100	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	3.7	30
101	On Bayesian Estimation of Marginal Structural Models. <i>Biometrics</i> , 2015, 71, 279-288.	1.4	29
102	Food Insecurity in HIV-Hepatitis C Virus Co-infected Individuals in Canada: The Importance of Co-morbidities. <i>AIDS and Behavior</i> , 2017, 21, 792-802.	2.7	29
103	Cannabis Consumption in People Living with HIV: Reasons for Use, Secondary Effects, and Opportunities for Health Education. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 204-213.	2.9	27
104	Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1507-1514.	2.0	26
105	Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1131-1138.	5.8	26
106	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	5.9	26
107	Risk of HCC With Hepatitis B Viremia Among HIV/HBV Coinfected Persons in North America. <i>Hepatology</i> , 2021, 74, 1190-1202.	7.3	26
108	Viral Pathogens Including Human Metapneumovirus Are the Primary Cause of Febrile Respiratory Illness in HIV-Infected Adults Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 297-301.	4.0	25

#	ARTICLE	IF	CITATIONS
109	Incidence and Predictors of Hepatic Steatosis and Fibrosis by Serum Biomarkers in a Large Cohort of Human Immunodeficiency Virus Mono-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv015.	0.9	25
110	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. <i>Aids</i> , 2020, 34, 237-244.	2.2	25
111	The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. <i>Aids</i> , 2004, 18, 1895-1904.	2.2	24
112	Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 521-526.	3.8	24
113	Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2017, 17, 246.	2.9	24
114	Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2004, 2, 521-532.	4.4	23
115	Trends in cause-specific mortality in HIV–hepatitis C coinfection following hepatitis C treatment scale-up. <i>Aids</i> , 2019, 33, 1013-1022.	2.2	23
116	Are we ready for home-based, self-testing for HIV?. <i>Future HIV Therapy</i> , 2008, 2, 515-520.	0.4	22
117	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1₂₀₀₉ and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2012, 13, 23-32.	2.0	22
118	Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. <i>Journal of Clinical Virology</i> , 2014, 60, 295-300.	3.1	22
119	Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. <i>Journal of the International AIDS Society</i> , 2015, 18, 20024.	3.0	22
120	Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfecting patients after hepatitis C therapy: a prospective cohort study. <i>HIV Clinical Trials</i> , 2015, 16, 100-110.	2.0	22
121	Viral suppression and viral rebound among young adults living with HIV in Canada. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Over</i>	1.0	22
122	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016, 2016, 1-34.	1.9	21
123	Evaluating the impact of health policies: using a difference-in-differences approach. <i>International Journal of Public Health</i> , 2019, 64, 637-642.	2.3	21
124	Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons. <i>Journal of Medical Virology</i> , 2006, 78, 1158-1163.	5.0	20
125	Didanosine, interferon-alfa and ribavirin. <i>Aids</i> , 2003, 17, 1001-1008.	2.2	18
126	Factors Associated With Discordance Between Absolute CD4 Cell Count and CD4 Cell Percentage in Patients Coinfected With HIV and Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2012, 54, 1798-1805.	5.8	18

#	ARTICLE	IF	CITATIONS
127	Modeling the impact of hepatitis C viral clearance on end-stage liver disease in an HIV co-infected cohort with targeted maximum likelihood estimation. <i>Biometrics</i> , 2014, 70, 144-152.	1.4	18
128	Segmented generalized mixed effect models to evaluate health outcomes. <i>International Journal of Public Health</i> , 2018, 63, 547-551.	2.3	18
129	Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada. <i>Journal of the International AIDS Society</i> , 2018, 21, e25197.	3.0	18
130	<i>Mycobacterium haemophilum</i> Epididymal Abscess in a Renal Transplant Patient. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2459-2460.	3.9	17
131	Noncirrhotic Portal Hypertension and Didanosine: A Re-Analysis. <i>Clinical Infectious Diseases</i> , 2011, 52, 154-155.	5.8	17
132	Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review. <i>Journal of Viral Hepatitis</i> , 2020, 27, 205-220.	2.0	17
133	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675.	1.0	16
134	Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2012, 26, 1789-1794.	2.2	16
135	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. <i>CMAJ Open</i> , 2014, 2, E318-E329.	2.4	16
136	The EVVA Cohort Study: Anal and Cervical Type-Specific Human Papillomavirus Prevalence, Persistence, and Cytologic Findings in Women Living With HIV. <i>Journal of Infectious Diseases</i> , 2017, 216, 447-456.	4.0	16
137	Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. <i>International Journal of Drug Policy</i> , 2019, 65, 41-49.	3.3	16
138	A randomized pilot study assessing the acceptability of rapid point-of-care hepatitis C virus (HCV) testing among male inmates in Montreal, Canada. <i>International Journal of Drug Policy</i> , 2020, 85, 102921.	3.3	16
139	A Review of Influenza Vaccine Immunogenicity and Efficacy in HIV-Infected Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 419-423.	1.9	15
140	A marginal structural model for multiple-outcome survival data: assessing the impact of injection drug use on several causes of death in the Canadian Co-infection Cohort. <i>Statistics in Medicine</i> , 2014, 33, 1409-1425.	1.6	15
141	Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. <i>BMC Infectious Diseases</i> , 2010, 10, 40.	2.9	14
142	Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine Among Treatment-Naive HIV-Infected Patients Initiating Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 38-46.	2.1	14
143	Significant differences in clinical outcomes between HIV-hepatitis C virus coinfecting individuals with and without injection drug use history. <i>Aids</i> , 2014, 28, 121-127.	2.2	14
144	HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus coinfected patients. <i>HIV Medicine</i> , 2015, 16, 24-31.	2.2	14

#	ARTICLE	IF	CITATIONS
145	Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models. <i>American Journal of Epidemiology</i> , 2016, 184, 249-258.	3.4	14
146	Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw050.	0.9	14
147	Association between depressive symptoms, CD4 count and HIV viral suppression among HIV-HCV co-infected people. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 643-649.	1.2	14
148	The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. <i>CMAJ Open</i> , 2019, 7, E674-E679.	2.4	14
149	Liver-related Events in Human Immunodeficiency Virusâ€infectd Persons With Occult Cirrhosis. <i>Clinical Infectious Diseases</i> , 2019, 69, 1422-1430.	5.8	14
150	Determinants of Liver Complications Among HIV/Hepatitis B Virusâ€Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 71-80.	2.1	14
151	CD127 Expression, Exhaustion Status and Antigen Specific Proliferation Predict Sustained Virologic Response to IFN in HCV/HIV Co-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e101441.	2.5	13
152	Correlates of drug use cessation among participants in the Canadian HIVâ€HCV Co-infection Cohort. <i>Drug and Alcohol Dependence</i> , 2014, 137, 121-128.	3.2	13
153	Tuberculosis Screening and Active Tuberculosis among HIV-Infected Persons in a Canadian Tertiary Care Centre. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 51-57.	1.9	12
154	Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfectd with HIV: a prospective cohort study. <i>CMAJ Open</i> , 2013, 1, E106-E114.	2.4	12
155	Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and Design. <i>AIDS Research and Treatment</i> , 2015, 2015, 1-11.	0.7	12
156	A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 531-539.	2.1	12
157	Medication nonadherence, multitablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression. <i>Aids</i> , 2018, 32, 1323-1332.	2.2	12
158	Delayed linkage to HIV care among asylum seekers in Quebec, Canada. <i>BMC Public Health</i> , 2019, 19, 1683.	2.9	12
159	Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 222, 787-797.	4.0	12
160	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1<sub>2009</sub> and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2012, 13, 23-32.	2.0	12
161	Rapid Testing at Labor and Delivery to Prevent Mother-To-Child Hiv Transmission in Developing Settings: Issues and Challenges. <i>Women's Health</i> , 2009, 5, 55-62.	1.5	11
162	A cloned CD15â€negative variant of HL60 cells is deficient in expression of FUT7 and does not adhere to cytokineâ€stimulated endothelial cells. <i>European Journal of Haematology</i> , 1999, 63, 42-49.	2.2	11

#	ARTICLE	IF	CITATIONS
163	Influence of Hepatitis C Virus Sustained Virological Response on Immunosuppressive Tryptophan Catabolism in ART-Treated HIV/HCV Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 254-262.	2.1	11
164	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020, 71, 2810-2817.	5.8	11
165	Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?. <i>Clinical Infectious Diseases</i> , 2021, 73, 468-477.	5.8	11
166	Who Needs Direct-Acting Antivirals for HCV? Challenges Faced in Advancing HCV Therapy for HIV-HCV-Coinfected Individuals. <i>Antiviral Therapy</i> , 2013, 18, 717-721.	1.0	10
167	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian Guidelines for Management and Treatment of HIV/Hepatitis C Coinfection in Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013, 24, 217-238.	1.9	10
168	Factors Associated with Late Initiation of Highly Active Antiretroviral Therapy among Young HIV-Positive Men and Women Aged 18 to 29 Years in Canada. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014, 13, 56-62.	1.5	10
169	Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv109.	0.9	10
170	Opioid use and risk of liver fibrosis in HIV/hepatitis C virus-coinfected patients in Canada. <i>HIV Medicine</i> , 2016, 17, 36-45.	2.2	10
171	Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz055.	0.9	10
172	Management and Treatment of Hepatitis C Virus in Patients with HIV and Hepatitis C Virus Coinfection: A Practical Guide for Health Care Professionals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2007, 18, 293-303.	1.9	9
173	CTN-194 (PICCO): Design of a trial of citalopram for the prevention of depression and its consequences in HIV-Hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. <i>Contemporary Clinical Trials</i> , 2008, 29, 617-630.	1.8	9
174	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. <i>American Journal of Epidemiology</i> , 2011, 174, 727-735.	3.4	9
175	Responder Interferon Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2016, 214, 80-86.	4.0	9
176	Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients. <i>Aids</i> , 2018, 32, 751-759.	2.2	9
177	Injection drug use, food insecurity, and HIV-HCV co-infection: a longitudinal cohort analysis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1322-1328.	1.2	9
178	Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: A national survey of Canadian infectious diseases physicians. <i>Canadian Liver Journal</i> , 2018, 1, 231-239.	0.9	9
179	Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada. <i>BMC Infectious Diseases</i> , 2019, 19, 982.	2.9	9
180	CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian Guidelines for the Treatment of Hepatitis C Infection in HIV-hepatitis C Coinfected Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014, 25, 311-320.	1.9	8

#	ARTICLE	IF	CITATIONS
181	Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial. <i>HIV Clinical Trials</i> , 2014, 15, 161-175.	2.0	8
182	Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C Coinfected Persons. <i>Clinical Infectious Diseases</i> , 2016, 62, 242-249.	5.8	8
183	Hepatitis C virus elimination: time for disruptive innovation. <i>Journal of the International AIDS Society</i> , 2019, 22, e25360.	3.0	8
184	Increased CD4/CD8 ratio normalization with implementation of current ART management guidelines. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 729-737.	3.0	8
185	Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. <i>Aids</i> , 2003, 17, 1001-8.	2.2	8
186	Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. <i>BMC Infectious Diseases</i> , 2017, 17, 266.	2.9	7
187	Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 697-704.	0.9	7
188	Evaluating Flexible Modeling of Continuous Covariates in Inverse-Weighted Estimators. <i>American Journal of Epidemiology</i> , 2019, 188, 1181-1191.	3.4	7
189	Brief Report: Persistence of Non-Vaccine Oncogenic HPV Genotypes in Quadrivalent HPV-Vaccinated Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 230-234.	2.1	7
190	Trends in hepatitis C virus seroprevalence and associated risk factors among men who have sex with men in Montréal: results from three cross-sectional studies (2005, 2009, 2018). <i>Sexually Transmitted Infections</i> , 2021, 97, 290-296.	1.9	7
191	Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort. <i>Aids</i> , 2013, 27, 2863-2872.	2.2	6
192	Impact of the Data Collection on Adverse Events of Anti-HIV Drugs Cohort Study on Abacavir Prescription among Treatment-Naïve, HIV-Infected Patients in Canada. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014, 13, 153-159.	1.5	6
193	High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine. <i>Journal of Clinical Immunology</i> , 2014, 34, 655-662.	3.8	6
194	The Impact of Sparse Follow-up on Marginal Structural Models for Time-to-Event Data. <i>American Journal of Epidemiology</i> , 2015, 182, kwv152.	3.4	6
195	Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfecting patients. <i>Aids</i> , 2016, 30, 1403-1411.	2.2	6
196	Hospitalizations in Immigrants and Nonimmigrants Diagnosed With Chronic Hepatitis C Infection in Québec. <i>Clinical Infectious Diseases</i> , 2016, 63, 1439-1448.	5.8	6
197	Impact of Food Insecurity on Depressive Symptoms Among HIV/HCV Co-infected People. <i>AIDS and Behavior</i> , 2017, 21, 3464-3472.	2.7	6
198	Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study. <i>BMC Infectious Diseases</i> , 2017, 17, 80.	2.9	6

#	ARTICLE	IF	CITATIONS
199	Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access. <i>Hepatology, Medicine and Policy</i> , 2017, 2, 8.	1.7	6
200	Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada. <i>Canadian Journal of Public Health</i> , 2017, 108, e169-e175.	2.3	6
201	Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. <i>Drug and Alcohol Dependence</i> , 2018, 185, 374-380.	3.2	6
202	Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging. <i>PLoS ONE</i> , 2018, 13, e0195148.	2.5	6
203	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. <i>PLoS ONE</i> , 2017, 12, e0176282.	2.5	6
204	Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. <i>International Journal of Drug Policy</i> , 2022, 103, 103627.	3.3	6
205	Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. <i>Aids</i> , 2010, 24, 2639-2644.	2.2	5
206	Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection – The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index. <i>PLoS ONE</i> , 2015, 10, e0129868.	2.5	5
207	Favourable IFNL3 Genotypes Are Associated with Spontaneous Clearance and Are Differentially Distributed in Aborigines in Canadian HIV-Hepatitis C Co-Infected Individuals. <i>International Journal of Molecular Sciences</i> , 2015, 16, 6496-6512.	4.1	5
208	A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada. <i>Antiviral Therapy</i> , 2016, 22, 325-335.	1.0	5
209	Injection Drug Use, Unemployment, and Severe Food Insecurity Among HIV-HCV Co-Infected Individuals: A Mediation Analysis. <i>AIDS and Behavior</i> , 2017, 21, 3496-3505.	2.7	5
210	Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV-HCV Coinfection. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.9	5
211	Tobacco smoking and HIV-related immunologic and virologic response among individuals of the Canadian HIV Observational Cohort (CANOC). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 982-991.	1.2	5
212	Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?. <i>International Journal of Drug Policy</i> , 2021, 96, 103343.	3.3	5
213	Missed Opportunities for Hepatocellular Carcinoma Screening in an HIV/Hepatitis C Virus-Coinfected Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 1339-1342.	5.8	4
214	Rejoinder – On Bayesian Estimation of Marginal Structural Models. <i>Biometrics</i> , 2015, 71, 299-301.	1.4	4
215	Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C. <i>HIV Medicine</i> , 2016, 17, 373-379.	2.2	4
216	Comparing direct acting antivirals for hepatitis C using observational data – Why and how?. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00650.	2.4	4

#	ARTICLE	IF	CITATIONS
217	Characterization of people living with HIV in a Montreal-based tertiary care center with COVID-19 during the first wave of the pandemic. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-7.	1.2	4
218	Management and Treatment of Hepatitis B Virus in Patients with Hiv Infection: A Practical Guide for Health Care Professionals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011, 22, 88-96.	1.9	3
219	Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV. <i>Vaccine</i> , 2020, 38, 3073-3078.	3.8	3
220	Prevalent and persistent oncogenic HPV types in a cohort of women living with HIV prior to HPV vaccination. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 150, 108-115.	2.3	3
221	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. <i>Journal of Infectious Diseases</i> , 2021, 224, 657-666.	4.0	3
222	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 214-224.	1.9	3
223	Semiparametric Bayesian inference for optimal dynamic treatment regimes via dynamic marginal structural models. <i>Biostatistics</i> , 2023, 24, 708-727.	1.5	3
224	Vaginal microbiota associated with oncogenic HPV in a cohort of HPV-vaccinated women living with HIV. <i>International Journal of STD and AIDS</i> , 2022, 33, 847-855.	1.1	3
225	Incomplete Modeling of the Effect of Antiretroviral Therapy on the Risk of Cardiovascular Events. <i>Clinical Infectious Diseases</i> , 2015, 61, 1206-1207.	5.8	2
226	Nasal Nitric Oxide Levels in HIV Infection: A Cross-Sectional Study. <i>AIDS Research and Treatment</i> , 2018, 2018, 1-6.	0.7	2
227	Tenofovir and emtricitabine resistance among antiretroviral-naïve patients in the Canadian Observational Cohort Collaboration: implications for PrEP. <i>Antiviral Therapy</i> , 2019, 24, 211-220.	1.0	2
228	Estimating an individual-level deprivation index for HIV/HCV coinfecting persons in Canada. <i>PLoS ONE</i> , 2021, 16, e0249836.	2.5	2
229	Potential interventions to support HCV treatment uptake among HIV co-infected people in Canada: Perceptions of patients and health care providers. <i>Canadian Liver Journal</i> , 0, , .	0.9	2
230	Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 277-279.	8.1	2
231	Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	2
232	Structured treatment interruptions in chronic HIV management: where next?. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 909-912.	4.4	1
233	Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B. <i>HIV Therapy</i> , 2009, 3, 189-207.	0.6	1
234	Virus subtype, ethnicity and CD4 decline in untreated HIV infection. <i>Future Virology</i> , 2014, 9, 337-340.	1.8	1

#	ARTICLE	IF	CITATIONS
235	The Rocky Road to viral hepatitis elimination: assuring access to antiviral therapy for <scp>ALL</scp> coinfecting patients from low to high income settings. Journal of the International AIDS Society, 2018, 21, e25073.	3.0	1
236	The Mediating Role of Depressive Symptoms in the Association Between Food Insecurity and HIV Related Health Outcomes Among HIV-HCV Co-Infected People. AIDS and Behavior, 2020, 24, 2188-2194.	2.7	1
237	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 396-404.	2.1	1
238	Barriers and facilitators related to HCV treatment uptake among HIV coinfecting populations in Canada: Patients and treatment provider perceptions. Canadian Liver Journal, 0, , .	0.9	1
239	Identifying risk factors for prevalent anal human papillomavirus type 16 infection in women living with HIV. PLoS ONE, 2022, 17, e0268521.	2.5	1
240	Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population in Canada. Clinical Infectious Diseases, 0, , .	5.8	1
241	Reply to Mandorfer et al. Clinical Infectious Diseases, 2013, 56, 905-906.	5.8	0
242	Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study. BMC Infectious Diseases, 2015, 15, 453.	2.9	0
243	Clinical and demographic predictors of antiretroviral efficacy in HIV-HBV co-infected patients. Jammi, 2021, 6, 137-148.	0.5	0
244	Use of Smoking Cessation Aids in a Convenience Sample of PLHIV in a Canadian Tertiary Care Clinic. Open AIDS Journal, 2019, 13, 1-6.	0.5	0
245	Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV-HCV co-infected population in Canada. Antiviral Therapy, 2022, 27, 135965352110676.	1.0	0